Upadacitinib Efficacy and Safety Meta-Analysis for Rheumatoid Arthritis

A systematic review and meta-analysis of randomized controlled trials published up to July 2025, evaluating the drug upadacitinib for rheumatoid arthritis. The analysis includes 9 trials with 5,237 participants, assessing efficacy via ACR20 response and safety endpoints. The document was authored by Yi-Heng Xu and uploaded to figshare in May 2026.

Use Cases

• Compare the efficacy of 15 mg vs. 30 mg upadacitinib doses based on ACR20 response rates.
• Assess the safety profile of upadacitinib based on reported adverse events, serious infections, and herpes zoster incidence.
• Inform clinical trial design for rheumatoid arthritis therapies based on the aggregated results from nine randomized controlled trials.
• Evaluate the benefit-risk balance of JAK1 inhibitor treatments for specific patient populations mentioned in the conclusion.

Strengths

• Analysis is based on 9 randomized controlled trials involving 5,237 participants, providing a substantial evidence base.
• Follows PRISMA guidelines and is registered with PROSPERO (CRD420251134541), indicating a structured methodology.
• Reports specific, quantified outcomes including odds ratios and confidence intervals for efficacy and safety.

Limitations

• The dataset is a single 105.5 KB PDF document; the underlying trial data is not provided in a structured, machine-readable format.
• Row count and column-level documentation are absent; data extraction for secondary analysis would require manual effort.
• The temporal coverage of the included trials is not specified beyond the search cutoff date of July 2025.

Provenance

Source

Systematic review of electronic databases (PubMed, Web of Science, Embase) for randomized controlled trials.

Collection Method

Meta-analysis performed using RevMan 5.4 software according to PRISMA guidelines.

Time Range

Trials from database inception to July 2025.

Freshness

Last updated 2026-05-20 05:23:48